Takeda Pharmaceutical (TAK) Depreciation & Amortization (CF) (2018 - 2026)

Takeda Pharmaceutical has reported Depreciation & Amortization (CF) for 9 years, with the latest figure at $1.0 billion in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 18.51% year-over-year to $1.0 billion in Q2 2026; TTM through Jun 2026 was $7.7 billion, a 54.04% increase from a year earlier, with the FY2026 full-year figure at $4.6 billion, down 8.01% from the prior year.
• Depreciation & Amortization (CF) was $1.0 billion for Q2 2026 at Takeda Pharmaceutical, down from $1.0 billion in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $4.7 billion in Q3 2023, with the low at $1.0 billion in Q2 2026.
• Average Depreciation & Amortization (CF) over 5 years is $1.8 billion, with a median of $1.3 billion recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) sank 72.42% in 2024, then surged 242.96% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $1.3 billion in 2022, then increased by 1.08% to $1.3 billion in 2023, then retreated by 2.83% to $1.2 billion in 2024, then gained by 0.73% to $1.2 billion in 2025, then slipped by 17.42% to $1.0 billion in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.0 billion (Q2 2026), $1.0 billion (Q1 2026), and $1.2 billion (Q4 2025), per Business Quant data.